Results for tag: "Hemophagocytic Lymphohistiocytosis Drug"

Hemophagocytic Lymphohistiocytosis (HLH) is a rare, life-threatening disorder of the immune system characterized by an excessive and uncontrolled activation of the immune system. It is caused by an overproduction of cytokines, which leads to inflammation and tissue damage. Treatment of HLH typically involves a combination of chemotherapy, immunosuppressive drugs, and supportive care. Oncology drugs are used to treat HLH, as they can help reduce inflammation and suppress the immune system. The HLH drug market is a rapidly growing segment of the oncology drug market. It is driven by the increasing prevalence of HLH, the development of new drugs, and the increasing demand for better treatments. The market is expected to grow at a steady rate in the coming years, as more drugs are developed and approved for use. Some of the major companies in the HLH drug market include Novartis, Pfizer, Merck, and Roche. Other companies such as Celgene, Gilead, and AbbVie are also active in the market. Show Less Read more